BACKGROUND: In this retrospective study, we analysed clinical, biochemical and molecular genetic data of 47 Czech patients with Single, Large-Scale Mitochondrial DNA Deletions (SLSMD). METHODS: The diagnosis was based on the long-range PCR (LX-PCR) screening of mtDNA isolated from muscle biopsy in 15 patients, and from the buccal swab, urinary epithelial cells and blood in 32 patients. RESULTS: A total of 57% patients manifested before the age of 16. We did not find any significant difference between paediatric and adult manifestation in either the proportion of patients that would develop extraocular symptoms, or the timespan of its progression. The survival rate in patients with Pearson Syndrome reached 60%. Altogether, five patients manifested with atypical phenotype not fulfilling the latest criteria for SLSMD. No correlation was found between the disease severity and all heteroplasmy levels, lengths of the deletion and respiratory chain activities in muscle. CONCLUSIONS: Paediatric manifestation of Progressive External Ophthalmoplegia (PEO) is not associated with a higher risk of multisystemic involvement. Contrary to PEO and Kearns-Sayre Syndrome Spectrum, Pearson Syndrome still contributes to a significant childhood mortality. SLSMD should be considered even in cases with atypical presentation. To successfully identify carriers of SLSMD, a repeated combined analysis of buccal swab and urinary epithelial cells is needed.

Department of Ophthalmology 1st Faculty of Medicine Charles University and General University Hospital U Nemocnice 2 128 08 Prague 2 Czech Republic

Department of Paediatrics 1st Faculty of Medicine Charles University and Thomayer Hospital Vídeňská 800 140 59 Prague 4 Czech Republic

Department of Paediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Ke Karlovu 2 128 08 Prague 2 Czech Republic

Department of Pathology and Molecular Medicine 2nd Faculty of Medicine Charles University and Motol University Hospital 5 Úvalu 84 150 06 Prague 5 Czech Republic

Zobrazit více v PubMed

Holt I.J., Harding A.E., Morgan-Hughes J.A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature. 1988;331:717–719. doi: 10.1038/331717a0. PubMed DOI

Mancuso M., Orsucci D., Angelini C., Bertini E., Carelli V., Comi G.P., Donati M.A., Federico A., Minetti C., Moggio M., et al. Redefining phenotypes associated with mitochondrial DNA single deletion. J. Neurol. 2015;262:1301–1309. doi: 10.1007/s00415-015-7710-y. PubMed DOI

Pitceathly R.D., Rahman S., Hanna M.G. Single deletions in mitochondrial DNA--molecular mechanisms and disease phenotypes in clinical practice. Neuromuscul. Disord. 2012;22:577–586. doi: 10.1016/j.nmd.2012.03.009. PubMed DOI

Chinnery P.F., DiMauro S., Shanske S., Schon E.A., Zeviani M., Mariotti C., Carrara F., Lombes A., Laforet P., Ogier H., et al. Risk of developing a mitochondrial DNA deletion disorder. Lancet. 2004;364:592–596. doi: 10.1016/S0140-6736(04)16851-7. PubMed DOI

Gustafson M.A., McCormick E.M., Perera L., Longley M.J., Bai R., Kong J., Dulik M., Shen L., Goldstein A.C., McCormack S.E., et al. Mitochondrial single-stranded DNA binding protein novel de novo SSBP1 mutation in a child with single large-scale mtDNA deletion (SLSMD) clinically manifesting as Pearson, Kearns-Sayre, and Leigh syndromes. PLoS ONE. 2019;14:e0221829. doi: 10.1371/journal.pone.0221829. PubMed DOI PMC

Rocha M.C., Rosa H.S., Grady J.P., Blakely E.L., He L., Romain N., Haller R.G., Newman J., McFarland R., Ng Y.S., et al. Pathological mechanisms underlying single large-scale mitochondrial DNA deletions. Ann. Neurol. 2018;83:115–130. doi: 10.1002/ana.25127. PubMed DOI PMC

Sato A., Nakada K., Shitara H., Kasahara A., Yonekawa H., Hayashi J. Deletion-mutant mtDNA increases in somatic tissues but decreases in female germ cells with age. Genetics. 2007;177:2031–2037. doi: 10.1534/genetics.107.081026. PubMed DOI PMC

Gorman G.S., Schaefer A.M., Ng Y., Gomez N., Blakely E.L., Alston C.L., Feeney C., Horvath R., Yu-Wai-Man P., Chinnery P.F., et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann. Neurol. 2015;77:753–759. doi: 10.1002/ana.24362. PubMed DOI PMC

Drachman D.A. Ophthalmoplegia plus. The neurodegenerative disorders associated with progressive external ophthalmoplegia. Arch. Neurol. 1968;18:654–674. doi: 10.1001/archneur.1968.00470360076008. PubMed DOI

Rowland L.P. Molecular genetics, pseudogenetics, and clinical neurology. The Robert Wartenberg Lecture. Neurology. 1983;33:1179–1195. doi: 10.1212/WNL.33.9.1179. PubMed DOI

Pearson H.A., Lobel J.S., Kocoshis S.A., Naiman J.L., Windmiller J., Lammi A.T., Hoffman R., Marsh J.C. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J. Pediatr. 1979;95:976–984. doi: 10.1016/S0022-3476(79)80286-3. PubMed DOI

Akman C.I., Sue C.M., Shanske S., Tanji K., Bonilla E., Ojaimi J., Krishna S., Schubert R., DiMauro S. Mitochondrial DNA deletion in a child with megaloblastic anemia and recurrent encephalopathy. J. Child Neurol. 2004;19:258–261. doi: 10.1177/088307380401900403. PubMed DOI

Tesarova M., Vondrackova A., Stufkova H., Veprekova L., Stranecky V., Berankova K., Hansikova H., Magner M., Galoova N., Honzik T., et al. Sideroblastic anemia associated with multisystem mitochondrial disorders. Pediatr. Blood Cancer. 2019;66:e27591. doi: 10.1002/pbc.27591. PubMed DOI

Amati-Bonneau P., Valentino M.L., Reynier P., Gallardo M.E., Bornstein B., Boissiere A., Campos Y., Rivera H., de la Aleja J.G., Carroccia R., et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy ‘plus’ phenotypes. Brain. 2008;131:338–351. doi: 10.1093/brain/awm298. PubMed DOI

Mazurova S., Tesarova M., Zeman J., Stranecky V., Hansikova H., Baxova A., Giertlova M., Lastuvkova J., Chovanova V., Rusnakova S., et al. Fatal neonatal nephrocutaneous syndrome in 18 Roma children with EGFR deficiency. J. Dermatol. 2020;47:663–668. doi: 10.1111/1346-8138.15317. PubMed DOI

Danhelovska T., Kolarova H., Zeman J., Hansikova H., Vaneckova M., Lambert L., Kucerova-Vidrova V., Berankova K., Honzik T., Tesarova M. Multisystem mitochondrial diseases due to mutations in mtDNA-encoded subunits of complex I. BMC Pediatr. 2020;20:41. doi: 10.1186/s12887-020-1912-x. PubMed DOI PMC

Yamashita S., Nishino I., Nonaka I., Goto Y. Genotype and phenotype analyses in 136 patients with single large-scale mitochondrial DNA deletions. J. Hum. Genet. 2008;53:598–606. doi: 10.1007/s10038-008-0289-8. PubMed DOI

Khambatta S., Nguyen D.L., Beckman T.J., Wittich C.M. Kearns-Sayre syndrome: A case series of 35 adults and children. Int. J. Gen. Med. 2014;7:325–332. doi: 10.2147/IJGM.S65560. PubMed DOI PMC

Dvorakova V., Kolarova H., Magner M., Tesarova M., Hansikova H., Zeman J., Honzik T. The phenotypic spectrum of fifty Czech m.3243A>G carriers. Mol. Genet. Metab. 2016;118:288–295. doi: 10.1016/j.ymgme.2016.06.003. PubMed DOI

Mancuso M., Klopstock T. Mitochondrial Myopathies, Chronic Progressive External Ophthalmoparesis, and Kearns-Sayre Syndrome. In: Mancuso M., Klopstock T., editors. Diagnosis and Management of Mitochondrial Disorders. Springer International Publishing; Cham, Switzerland: 2019. pp. 141–150.

Siciliano G., Viacava P., Rossi B., Andreani D., Muratorio A., Bevilacqua G. Ocular myopathy without ophthalmoplegia can be a form of mitochondrial myopathy. Clin. Neurol. Neurosurg. 1992;94:133–141. doi: 10.1016/0303-8467(92)90070-J. PubMed DOI

Broomfield A., Sweeney M.G., Woodward C.E., Fratter C., Morris A.M., Leonard J.V., Abulhoul L., Grunewald S., Clayton P.T., Hanna M.G., et al. Paediatric single mitochondrial DNA deletion disorders: An overlapping spectrum of disease. J. Inherit. Metab. Dis. 2015;38:445–457. doi: 10.1007/s10545-014-9778-4. PubMed DOI PMC

Manea E.M., Leverger G., Bellmann F., Stanescu P.A., Mircea A., Lebre A.S., Rotig A., Munnich A. Pearson syndrome in the neonatal period: Two case reports and review of the literature. J. Pediatr. Hematol. Oncol. 2009;31:947–951. doi: 10.1097/MPH.0b013e3181bbc4ef. PubMed DOI

Lee S.J., Na J.H., Han J., Lee Y.M. Ophthalmoplegia in Mitochondrial Disease. Yonsei Med. J. 2018;59:1190–1196. doi: 10.3349/ymj.2018.59.10.1190. PubMed DOI PMC

Farruggia P., Di Cataldo A., Pinto R.M., Palmisani E., Macaluso A., Valvo L.L., Cantarini M.E., Tornesello A., Corti P., Fioredda F., et al. JIMD Reports. Volume 26. Springer; Berlin/Heidelberg, Germany: 2016. Pearson Syndrome: A Retrospective Cohort Study from the Marrow Failure Study Group of A.I.E.O.P. (Associazione Italiana Emato-Oncologia Pediatrica) pp. 37–43. PubMed DOI PMC

Bosbach S., Kornblum C., Schroder R., Wagner M. Executive and visuospatial deficits in patients with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome. Brain. 2003;126:1231–1240. doi: 10.1093/brain/awg101. PubMed DOI

Garcia-Cazorla A., Quadros E.V., Nascimento A., Garcia-Silva M.T., Briones P., Montoya J., Ormazabal A., Artuch R., Sequeira J.M., Blau N., et al. Mitochondrial diseases associated with cerebral folate deficiency. Neurology. 2008;70:1360–1362. doi: 10.1212/01.wnl.0000309223.98616.e4. PubMed DOI

Ormazabal A., Garcia-Cazorla A., Perez-Duenas B., Gonzalez V., Fernandez-Alvarez E., Pineda M., Campistol J., Artuch R. Determination of 5-methyltetrahydrofolate in cerebrospinal fluid of paediatric patients: Reference values for a paediatric population. Clin. Chim. Acta. 2006;371:159–162. doi: 10.1016/j.cca.2006.03.004. PubMed DOI

Pineda M., Ormazabal A., Lopez-Gallardo E., Nascimento A., Solano A., Herrero M.D., Vilaseca M.A., Briones P., Ibanez L., Montoya J., et al. Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion. Ann. Neurol. 2006;59:394–398. doi: 10.1002/ana.20746. PubMed DOI

Quijada-Fraile P., O’Callaghan M., Martin-Hernandez E., Montero R., Garcia-Cazorla A., de Aragon A.M., Muchart J., Malaga I., Pardo R., Garcia-Gonzalez P., et al. Follow-up of folinic acid supplementation for patients with cerebral folate deficiency and Kearns-Sayre syndrome. Orphanet. J. Rare Dis. 2014;9:217. doi: 10.1186/s13023-014-0217-2. PubMed DOI PMC

Serrano M., Garcia-Silva M.T., Martin-Hernandez E., O’Callaghan Mdel M., Quijada P., Martinez-Aragon A., Ormazabal A., Blazquez A., Martin M.A., Briones P., et al. Kearns-Sayre syndrome: Cerebral folate deficiency, MRI findings and new cerebrospinal fluid biochemical features. Mitochondrion. 2010;10:429–432. doi: 10.1016/j.mito.2010.04.001. PubMed DOI

Pardo Ruiz E., Maturana Martinez D., Vazquez Lopez M., Ruiz Martin Y. Kearns-Sayre syndrome: Absence of clinical response to treatment with oral folinic acid. Neurologia. 2019;34:618–620. doi: 10.1016/j.nrl.2017.01.005. PubMed DOI

Tanji K., Schon E.A., DiMauro S., Bonilla E. Kearns-sayre syndrome: Oncocytic transformation of choroid plexus epithelium. J. Neurol. Sci. 2000;178:29–36. doi: 10.1016/S0022-510X(00)00354-3. PubMed DOI

Allen R.J., DiMauro S., Coulter D.L., Papadimitriou A., Rothenberg S.P. Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann. Neurol. 1983;13:679–682. doi: 10.1002/ana.410130620. PubMed DOI

Lopez-Gallardo E., Lopez-Perez M.J., Montoya J., Ruiz-Pesini E. CPEO and KSS differ in the percentage and location of the mtDNA deletion. Mitochondrion. 2009;9:314–317. doi: 10.1016/j.mito.2009.04.005. PubMed DOI

Varhaug K.N., Nido G.S., de Coo I., Isohanni P., Suomalainen A., Tzoulis C., Knappskog P., Bindoff L.A. Using urine to diagnose large-scale mtDNA deletions in adult patients. Ann. Clin. Transl. Neurol. 2020;7:1318–1326. doi: 10.1002/acn3.51119. PubMed DOI PMC

Should Patients with Kearns-Sayre Syndrome and Corneal Endothelial Failure Be Genotyped for a TCF4 Trinucleotide Repeat, Commonly Associated with Fuchs Endothelial Corneal Dystrophy?